Filing Flows › Nurix Therapeutics (NRIX) › Q2 FY26
Nurix Therapeutics (NRIX) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Jul 9, 2026
Nurix Therapeutics (NRIX) reported revenue of $9.0M for the second quarter fiscal 2026 (Q2 FY26), -79% from a year earlier and +45% from the quarter before.
Nurix Therapeutics, Q2 FY26: revenue $9.0M (-80% year over year), net loss $89.5M, operating cash flow −$96.6M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | +45% | -79% |
| Operating profit | −$94.2M | — | — |
| Net earnings | −$89.5M | — | — |
| Operating cash flow | −$96.6M | — | — |
What changed
Revenue was $9.0M in Q2 FY26, down 79% year over year and up 45% from the previous quarter.
Operating costs exceeded revenue by $94.2M, an operating margin of -1041.7%. Total costs grew 12% against a revenue fall of 79%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $89.5M, wider than the previous quarter's $87.2M loss.
Operating cash flow was −$96.6M. Non-cash charges added back $2.3M of depreciation and amortization and $11.4M of share-based compensation. Working capital and other items used $20.7M. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$98.5M.
Questions
What was Nurix Therapeutics' revenue in the second quarter fiscal 2026?
Nurix Therapeutics (NRIX) reported revenue of $9.0M for the second quarter fiscal 2026 (Q2 FY26), -79% from a year earlier and +45% from the quarter before.
Source: Nurix Therapeutics 10-Q on SEC EDGAR.